Ranibizumab Plus Panretinal Photocoagulation versus Panretinal Photocoagulation Alone for High-Risk Proliferative Diabetic Retinopathy (PROTEUS Study)
Comparison of the efficacy of ranibizumab (RBZ) 0.5 mg intravitreal injections plus panretinal photocoagulation (PRP) versus PRP alone in the regression of the neovascularization (NV) area in subjects with high-risk proliferative diabetic retinopathy (HR-PDR) over a 12-month period.
Source: Ophthalmology - Category: Opthalmology Authors: Jo ão Figueira, Emily Fletcher, Pascale Massin, Rufino Silva, Francesco Bandello, Edoardo Midena, Monica Varano, Sobha Sivaprasad, Haralabos Eleftheriadis, Geeta Menon, Miguel Amaro, Sarah Ayello Scheer, Catherine Creuzot-Garcher, João Nascimento, Dalil Tags: Original Article Source Type: research